中文

华仁药业 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-24
ItemAmountY/Y
Revenue¥0.31B+2.1%
Gross profit¥0.10B
Operating income¥0.02B
Net income¥0.02B+1.6%
Gross margin33.2%Net margin 5.4%
Revenue Q/Q-10.2%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.21B66.8%
R&D¥0.01B4.5%
SG&A¥0.05B17.2%
Tax & other¥0.01B2.0%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

向日葵万讯自控顺网科技长盈精密东方日升瑞普生物经纬辉开阳谷华泰ST亚光*ST聆达锐奇股份银河磁体

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies